Oramed Pharmaceuticals price to sales ratio ORMP

Market value divided by revenue over the last twelve months, since 2017.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 88.0×; Aug 2026
10-year median: 34.5×
10-year range: -562× to 200×
Peer median: 1.4×

Oramed Pharmaceuticals' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Aug 2026, at 88.0×.

On the days it had one over the last ten years, its median was 34.5×, from -562× in Oct 2017 to 200× in Jun 2017.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	88.0×	66.9×	95.6×
2025	n/m a value too high to mean anything
2024	70.9×	44.5×	90.1×
2023	46.1×	26.7×	167×
2022	175×	53.1×	175×
2021	184×	39.3×	184×
2020	37.0×	19.2×	39.7×
2019	33.3×	16.9×	34.5×
2018	21.9×	11.5×	34.3×
2017	35.0×	-562×	200×

Against its peers

Companies in Drug Manufacturers - General nearest Oramed Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
ORMPOramed Pharmaceuticals	n/m
NATRNatures Sunshine Products	0.4×
LFVNLifevantage	0.4×
SPROSpero Therapeutics	1.4×
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
ATNMActinium Pharmaceuticals	n/m
COLLCollegium Pharmaceutical	0.9×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Oramed Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.